Treatment of generalized scleroderma with inhibitors of collagen synthesis.
Clinical evaluation of scleroderma and the urinary excretion of collagen specific amino acids and uronic acid indicate disease activity and have become a guide for treatment. During an experimental search for inhibitors of the synthesis of collagen and ground substance glycosaminoglycans, a few connective-tissue active agents were selected for therapy of scleroderma: D-penicillamine, benzyl-penicillin-diethylamino-ethylester-hydroiodide, L-glutamine, hydralazine, glucocorticoids, dextro-thyroxine, L-dopa, diphenylhydantion, chlorpromazine, and (+) catechine. Treatment for several years was required to bring about an arrest of progression in 89% of the patients, a regression in three-quarters, and subtotal or total recovery in more than 40%. Indications of favorable prognosis are youth, short disease history, a high total dose of agent, and long duration of the treatment.
D002392:Catechin / Q000627:therapeutic use; D002746:Chlorpromazine / Q000627:therapeutic use; D003094:Collagen / Q000037:antagonists & inhibitors*; D003918:Dextrothyroxine / Q000627:therapeutic use; D005973:Glutamine / Q000627:therapeutic use; D006801:Humans; D006830:Hydralazine / Q000627:therapeutic use; D007980:Levodopa / Q000627:therapeutic use; D010396:Penicillamine / Q000627:therapeutic use; D010400:Penicillin G / Q000031:analogs & derivatives / Q000627:therapeutic use; D010672:Phenytoin / Q000627:therapeutic use; D011241:Prednisone / Q000627:therapeutic use; D012595:Scleroderma, Systemic / Q000188:drug therapy*
D005973:Glutamine; D006830:Hydralazine; D007980:Levodopa; D003918:Dextrothyroxine; D010672:Phenytoin; C010207:lactopen; D002392:Catechin; D003094:Collagen; D010396:Penicillamine; D010400:Penicillin G; D002746:Chlorpromazine; D011241:Prednisone